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Mitochondrial Complex III Deficiency
Associated with a Homozygous Mutation in UQCRQ
Ortal Barel,1 Zamir Shorer,2 Hagit Flusser,2 Rivka Oﬁr,1 Ginat Narkis,1 Gal Finer,1 Hanah Shalev,2
Ahmad Nasasra,2 Ann Saada,3 and Ohad S. Birk1,4,*
A consanguineous Israeli Bedouin kindred presented with an autosomal-recessive nonlethal phenotype of severe psychomotor retarda-
tion and extrapyramidal signs, dystonia, athetosis and ataxia, mild axial hypotonia, and marked global dementia with defects in verbal
and expressive communication skills. Metabolic workup was normal except for mildly elevated blood lactate levels. Brain magnetic
resonance imaging (MRI) showed increased density in the putamen, with decreased density and size of the caudate and lentiform nuclei.
Reduced activity speciﬁcally of mitochondrial complex III and variable decrease in complex I activity were evident in muscle biopsies.
Homozygosity of affected individuals to UQCRB and to BCSIL, previously associated with isolated complex III deﬁciency, was ruled out.
Genome-wide linkage analysis identiﬁed a homozygosity locus of approximately 9 cM on chromosome 5q31 that was further narrowed
down to 2.14 cM, harboring 30 genes (logarithm of the odds [LOD] score 8.82 at q ¼ 0). All 30 genes were sequenced, revealing a single
missense (p.Ser45Phe) mutation in UQCRQ (encoding ubiquinol-cytochrome c reductase, complex III subunit VII, 9.5 kDa), one of the
ten nuclear genes encoding proteins of mitochondrial complex III.Mitochondrial complex III, located within the mitochon-
drial inner membrane, catalyzes the transfer of electrons
from succinate and nicotinamide adenine dinucleotide-
linked dehydrogenases to mitochondrially encoded cyto-
chrome b (MT-CYB [MIM 516020]) and utilizes the energy
to translocate protons from themitochondrial matrix to its
exterior.1 Complex III is composed of ten nuclear-encoded
subunits and one mitochondrial-encoded subunit
(MT-CYB).1 Although rare, isolated complex III deﬁciency
has been detected in a heterogeneous group of neuromus-
cular and nonneuromuscular disorders in children and
adults.1–9 Different pathogenic mutations in MT-CYB
have been described,2–5 whereas nuclear mutations have
so far been identiﬁed only in two genes: the BCS1-like
(BCS1L [MIM 603647]) gene, encoding a complex III
assembly factor on chromosome 2q33,6–8 and the UQCRB
gene (ubiquinol-cytochrome c reductase binding protein
[MIM 191330]), encoding subunit VI (chromosome
8q22) of the complex.9
MT-CYB is a highly evolutionarily conserved hydropho-
bic protein containing eight or nine transmembrane do-
mains and two heme groups. To date, about 27 different
mutations have been identiﬁed in cytochrome b, mostly
in patients with skeletal muscle weakness and exercise in-
tolerance.1,4 Most patients with MTCYB mutations have
sporadic myopathy-rhabdomyolysis associated with rag-
ged-red ﬁbers. Some of these patients have isolated com-
plex III defects, whereas other presentations can be associ-
ated with a defect involving complexes I and III because of
the structural interdependence of these complexes.10
Mutations in the autosomal BCS1L gene had previously
been found to cause mitochondrial complex III deﬁciency
manifested by neonatal renal tubulopathy, encephalopa-The Amthy, and liver failure,7 as well as the syndromes GRACILE8
(a severe disorder of intrauterine growth retardation, ami-
noaciduria, cholestasis, iron overload, lactic acidosis, and
early death; MIM 603358) and Bjornstad9 (an autosomal-
recessive disorder characterized by sensorineural hearing
loss and pili torti; MIM 262000). A single patient with a
homozygous deletion in the autosomal gene UQCRB was
shown to have isolated defective complex III function
with clinical hypoglycemia and lactic acidosis11 (MIM
191330). We now describe a severe novel autosomal-reces-
sive neurological phenotype of a complex III defect
associated with a mutation in UQCRQ, encoding ubi-
quinol-cytochrome c reductase, complex III subunit VII,
9.5 kDa.
A large consanguineous inbred Israeli Bedouin kindred
presented with a previously unreported autosomal-reces-
sive syndrome. The severe neuromuscular phenotype
affected a total of 25 individuals (Figure 1). Twenty of the
affected individuals were available for detailed clinical
and molecular analyses. The study was approved by the
Soroka University Medical Center Institutional Review
Board and by the Israel National Helsinki Committee in
Genetics, and informed consent was obtained from all
individuals tested. The abnormal phenotype was markedly
uniform and consisted of severe psychomotor retardation
and extrapyramidal signs. Affected individuals seemed
normal at birth without any dysmorphic features. During
the ﬁrst few months of life, the prominent clinical feature
was failure to achieve normal developmental milestones.
By age 2–3 years, extrapyramidal signs were evident in
all patients, presenting with dystonic postures, athetoid
movements, and ataxia. All affected individuals had
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demonstrated restlessness, marked global dementia, and
severe defects in verbal receptive communication and
near total absence of expressive communication skills,
with inability to express any words at any age. Mild axial
hypotonia, increased tone in the upper and lower limbs,
and increased deep tendon reﬂexes in all four extremities
with inability to walk unsupported were evident in all
patients. Cranial nerves were intact and ophthalmologic
exam was normal. The phenotype is not lethal, with
some affected individuals surviving well into their thirties.
Electroencephalogram (EEG) demonstrated nonspeciﬁc
mild generalized slowing. Brain magnetic resonance imag-
ing (MRI) done in ﬁve patients showed bilateral symmetric
abnormal ﬁndings in the basal ganglia (Figure 2), with
increased density in the putamen and decreased density
and size of the caudate and Globus pallidum nuclei. There
was no involvement of the brain-stem area. Audiograms
and karyotypes were normal. A thorough metabolic work
up was done: All laboratory values were within normal
limits except plasma lactate, which ranged from slightly
to signiﬁcantly increased levels (1.7–5.2 mM, mean value
3.3 mM; control range < 1.55 mM). Cerbrospinal ﬂuid
lactate was measured in a single patient (individual 173,
Figure 1) and was slightly elevated (2.8 mM; control range
< 2.2 mM). Muscle biopsies were done in three of the
affected individuals—patients 99, 109, and 177 (Figure 1),
ages 3, 15 and 2 years, respectively. Microscopic examina-
tion of muscle biopsies was nonspeciﬁc: The overall archi-
tecture of the skeletal muscle was preserved. There were
some myopathic changes reﬂected by a borderline mild
increase in variation in ﬁber size with few sporadic ﬁbers
demonstrating internal nuclei, as well as scattered regener-
ating ﬁbers demonstrated by alpha-fetal myosin stain
(positive in some 10% of the muscle ﬁbers). There was
no evidence of ragged-red ﬁbers or mitochondrial aggre-
Figure 1. Pedigree of Affected Israeli-
Bedouin Kindred
Solid and open symbols represent affected
and unaffected individuals, respectively.
All affected individuals are offspring of
consanguineous marriages. The numbers
denote individuals whose DNA samples were
analyzed. (A), (B), and (C) are branches of
a single extended kindred, remotely related
(not first or second degree).
gates, nor of group atrophy of muscle
ﬁbers, inﬂammation, accumulation
of lipid or glycogen, or replacement
of muscle ﬁbers by ﬁbrous or adipose
tissue. ATPase stains demonstrated
preserved ﬁber type distribution. Im-
munohistochemical stains for spec-
trin, 50-DAG, merosin, and dystro-
phin 1,2,3 were positive. Electron
microscopy (EM) studies done on
one of the biopsies demonstrated no mitochondrial struc-
tural abnormality. As demonstrated in Table 1, activities of
the mitochondrial respiratory chain enzymatic complexes
in muscle biopsies of these three patients showed 34%–
56% reduction of antimycin-sensitive ubiquinol-cyto-
chrome c reductase (complex III) with variable decreases in
rotenone-sensitive NADH-cytochrome c reductase (com-
plex IþIII) and rotenone-sensitive NADH-CoQ reductase
(complex I) (assays done as previously described12,13).
On the basis of the consanguinity of the families studied,
we assumed that the phenotype was a consequence of
a founder effect. Homozygosity of affected individuals at
the genomic loci of BCSIL7–9 and UQCRB,11 previously
associated with isolated complex III deﬁciency, was ruled
out (data not shown).We thus went on to study 11 affected
individuals and ﬁve healthy individuals by genome-wide
linkage analysis with 400 ﬂuorescent end-labeled polymor-
phic markers (ABI PRISM Linkage Mapping Set MD10
[Applied Biosystems]) as previously described.14 Noninfor-
mative regions were excluded with additional adjacent
microsatellite markers (data not shown). We identiﬁed
only a single locus in which most affected individuals
demonstrated increased homozygosity, whereas all obliga-
tory carriers tested were shown to be heterozygous (data
not shown). The locus, spanning approximately 9 cM (cor-
responding to 15.84 Mb) on chromosome 5q31, resides
between marker D5S471 (homozygosity in ﬁve of seven
affected individuals) and D5S2115 (homozygosity in eight
of 11 affected individuals). Fine mapping of the locus was
done, testing DNA samples of the 62 available family
members (20 affected and 42 nonaffected) with additional
polymorphic markers adjacent to the interval between
D5S471 and D5S2115: D5S471, D5S503, D5S1712,
D5S1975, D5S2059, D5S804, D5S2078, D5S642,
D5S2057, D5S1984, D5S2002, D5S_2, D5S2497,1212 The American Journal of Human Genetics 82, 1211–1216, May 2008
D5S2117, D5S2053, D5S1995, and D5S2115; D5S_2 is
polymorphic marker designed with Tandem Repeats
Finder15 (sequences available on request).
As seen in Figure 3A, an approximately 2.14 cM interval
of homozygosity common to all affected individuals in the
family lies between markers D5S2057 and D5S2497. Three
affected siblings (184, 182, and 185) in the family
presented with a crossing-over event at D5S2057, setting
the upper limit of the homozygosity interval at D5S2057
(Figure 3A). The affected individual 129 presented with
a crossing-over event at D5S2497, setting the lower limit
of the homozygosity interval at D5S2497. Linkage was
demonstrated by two-point analysis with SUPERLINK,16
with a logarithm of the odds [LOD] score of 8.82 at q ¼ 0
for marker D5S_2 (data not shown).
Thecommonhaplotype indicatedaminimalcandidate in-
terval: a 2 Mb region that contains 30 known or predicted
genes. Sequencing of the coding regions of all 30 genes
within the 5q31 locus (other than UQCRQ) revealed nomu-
tations (data not shown). As shown in Figure 4, sequence
analysis of UQCRQ (GenBank accession number
Figure 2. MRI Studies of Affected Individual 133
at Age 2 Years
Bilateral symmetrical abnormal findings in the basal
ganglia, with increased density in the putamen and
decreased density and size of the caudate and globus
pallidum nuclei.
Table 1. Enzymatic Activities of the Mitochondrial
Respiratory Chain
Sample
Assay Control, n ¼ 50 99 109 177
Citrate synthasea 25205 760 3300 1800 2500
Complex Ia 2275 70 128 (45%) 157 (96%) 118 (52%)
Complex IþIIIa 6085 213 326 (43%) 306 (70%) 450 (74%)
Complex IIþIIIa 2955 101 318 (86%) 190 (89%) 340 (114%)
Complex IIa 2105 60 208 (79%) 145 (94%) 196 (92%)
Complex IIIa 25005 1400 2100 (62%) 1290 (66%) 1200 (44%)
Complex IVb 17.4 5 6.9 21.0 (95%) 12.1 (94%) 14.2 (80%)
Complex Va 5365 193 869 (135%) 350 (94%) 425 (82%)
Enzymatic activities of the five mitochondrial respiratory-chain complexes
were measured in isolated muscle mitochondria. Values in parentheses pres-
ent activities as a percentage of the control mean, normalized for citrate
synthase activity.
a Expressed as nmol/min/mg.
b Expressed as velocity constant.
NM_014402.4) revealed a c.208C/Tmutation
inexon2, replacing serine atposition45byphe-
nylalanine (p.Ser45Phe) in the encodedprotein,
UQCRQ, complex III subunit VII, 9.5 kDa. The
mutation abolishes a recognition site of the
restriction enzymeHinfI, allowing easy analysis
of the entire kindred and controls (polymerase
chain reaction [PCR] ampliﬁcation primers: 50- CCGCACGT
CTTCACTAAAGG-30 and 50-CTTAAGGGCGGTCAGGAA
TA-30). Analysis of all 62 DNA samples of the kindred was
compatible with themutation being associated with the dis-
ease phenotype, implying full penetrance (data not shown;
PCR primer sequences and ampliﬁcation procedures used
for sequencing are available on request). The mutation was
not found in any of 600 chromosomes from ethnically
matched controls tested by restriction analysis, or in any of
470 chromosomes from unrelated non-Bedouin individuals
of various ethnic backgrounds. It should be noted that the
serine at position 45 of UQCRQ is replaced in some species
by glutamine or arginine but is not replaced by phenylala-
nine in any of the homologs of this gene in all organisms
sequenced to date. Whereas serine, glutamine and arginine
have aliphatic side chains, phenylalanine has an aromatic
side chain, leading to a signiﬁcantly different three-dimen-
sional structure. Three-dimensional modeling of the Bovine
Mitochondrial bc1 Complex17 (which contains the UQCRQ
homolog) suggests that the Ser45 lies at a critical hinge posi-
tion likely determining the orientation of the extramem-
brane domain of the molecule.18 Thus, we assume that an
amino acid that is signiﬁcantly structurally different at this
position alters the orientation of this extramembrane do-
main. This is in line with the signiﬁcant yet relatively mild
effect on complex III activity and the changes seen in com-
plex I activity in affected individuals, probably mediated by
themutationalteringthesupramolecular structureof themi-
tochondrial respiratory chain. It has beendemonstrated that
a fully assembled complex III is essential for the stability and
activity of complex I.19,20 Thus, our results speciﬁcally con-
ﬁrm the structural dependency between complexes I and
III that was previously demonstrated in patients carrying
cytochromebmutations, associatedwithdecreasedcomplex
I activity.10,19 It is noteworthy that no signiﬁcant changes
were found in other complexes (in contrast with some other
mitochondrial syndromes, such as the recently described
ubiquinone deﬁciency).21
Only minor morphological changes were seen in muscle
biopsies of affected individuals. This is not surprising: Al-
though MTCYB mutations are associated with ragged-redThe American Journal of Human Genetics 82, 1211–1216, May 2008 1213
Figure 3. Defining the Disease-Associated Locus
(A) Partial pedigree of the large Israeli-Bedouin kindred. The affected haplotype is shaded. Physical distances between the markers are
shown.
(B and C) Fine mapping of the 5q31 locus. In (B), the disease-associated haplotype is boxed. Minimal homozygosity locus associated with
the disease is defined between the markers D5S2057 and D5S2497 (gray box). (C) shows a schematic presentation of the defined locus.ﬁbers,2–5 BCS1L mutations are not.7–9 The only report on
the UQCRB gene mutation is incomplete in this regard.11
The high LOD score, the lack of mutations in any of the
other genes in the deﬁned genomic locus, and the absence
of the p.Ser45Phemutation in 1070 control chromosomes,1214 The American Journal of Human Genetics 82, 1211–1216, Maytogether with the fact that UQCRQ is a component of com-
plex III—consistent with the reduced complex III activity
in affected individuals—heavily imply that the UQCRQ
mutation described is the basis for this severe phenotype.
We thus suggest that a homozygous mutation in UQCRQ2008
is associated with defective function of mitochondrial
complex III, leading to a severe autosomal-recessive
neurological phenotype.
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A genome-wide scan is available at http://www.ajhg.org/.
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